Pharmaceutical

Daiichi Sankyo and MSD withdraw US application for lung cancer BLA

Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).

May 30, 2025 - 06:00
Daiichi Sankyo and MSD withdraw US application for lung cancer BLA
Daiichi and MSD have voluntarily withdrawn the BLA in the US for their patritumab deruxtecan for treating non-small cell lung cancer (NSCLC).
Read the original article

Tags:

Previous Article

New Study Reveals Depression Raises Dementia Risk in Midlife and Beyond

Next Article

HHS cancels $766m bird flu vaccine contract with Moderna

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: LabCentral, a crucial Boston incubator for drug discovery, is slated to grow amid industry slowdown

STAT+: LabCentral, a crucial Boston incubator for drug ...

Jan 2, 2024

Now 18, the first child to ever receive CAR-T cancer therapy is ready for a new identity

Now 18, the first child to ever receive CAR-T cancer th...

May 3, 2023

UK MHRA strengthens regulations on fluoroquinolone antibiotics

UK MHRA strengthens regulations on fluoroquinolone anti...

Jan 23, 2024